Saturday, February 14, 2015 4:08:03 PM
The fact that there has been tumour shrinkage in this phase 1 trial is also quite encouraging. Many are watching closely for the final results. Especially, patients that may want to enter the phase 2 Kevetrin trial.
Brilacidin has derisked this investment as it has been moved forward in trial. The dose optimization of the 2b was brilliant since it appears to have solved the issues from the earlier 2a. And, that one dose vs 7 dose of daptomycin can't be ignored. Patient compliance won't be an issue and hospital stays will be shortened.
In Reply to 'To infinity and beyond!'
Interesting reading. Many posts suggest the previous research and previous trials in mice etc guarantee success for Kevetrin. Somewhere there is a good summary article that details all the various stages where once very promising drugs failed, but I cannot see taking the time to find it because I thought it to be common knowledge. Of course the drug can still fail.
Now though is an exciting time to be watching CTIX since things are picking up : setting doses and actually enrolling patients then seeing if K really helps cancer pts.
Plenty of anti physician sentiment out there, unsure why. I would assume that I am neither smarter nor dumber than all of you, and I would never suggest otherwise. At this stage in my life(57) I find that I am enamored less of smarts and more of effort, and hard work.
At some point I hope to be of some value to the board, based on seeing patients most days with celllulitis, and I will be able to tell you the buzz on Brilacidin, and whether the Infectious Disease consultant is sticking with Vancomycin and why, etc. And I would hope to see patients in the ED on K, such as the woman I saw yest with ovarian CA, widely metastatic, and struggling.
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM